Ulric Duncan, MD
Gastroenterology · Southaven, MSNPI 1518908854
Payments from drug & device makers
Across 923 payments — averaging $158.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$75K
- AbbVie$36K
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- Genentech USA, Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$1K
- plus $7K from 28 others
Across 6 payments — averaging $161.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$967
What the payments were for
- Travel & lodging$1,5257%
- Food & beverage$19,80792%
- Education$2041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 17 | $75,448 |
| AbbVie(2 entities) | 353 | $36,094 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $22,999 |
| Genentech USA, Inc. | 4 | $1,779 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 106 | $1,713 |
| Johnson & Johnson | 60 | $1,299 |
| Gilead | 59 | $1,222 |
| Madrigal Pharmaceuticals | 22 | $853 |
| Pfizer | 44 | $779 |
| Lilly USA, LLC | 23 | $642 |
| Ironwood Pharmaceuticals, Inc | 27 | $469 |
| Nestle Healthcare Nutrition Inc. | 26 | $453 |
| Covidien LP | 3 | $366 |
| Ardelyx, Inc. | 13 | $338 |
| Intercept Pharmaceuticals, Inc. | 15 | $330 |
| Novo Nordisk | 6 | $294 |
| Medtronic(2 entities) | 4 | $198 |
| Braintree Laboratories, Inc. | 23 | $193 |
| QOL Medical, LLC | 9 | $184 |
| Aimmune Therapeutics, Inc. | 9 | $168 |
| Sanofi | 4 | $116 |
| Phathom Pharmaceuticals, Inc. | 9 | $116 |
| Bristol Myers Squibb | 7 | $99 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| Sandoz | 3 | $83 |
| Mauna Kea Technologies, Inc. | 4 | $79 |
| Redhill Biopharma Inc. | 4 | $70 |
| Evoke Pharma, Inc. | 4 | $59 |
| Intuitive Surgical | 1 | $48 |
| Fresenius Kabi USA, LLC | 3 | $46 |
| Merck | 2 | $35 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Bausch Health US, LLC | 1 | $21 |
| Celltrion USA Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$146,734 in reported general payments places this provider in the 90th percentile of 127 gastroenterology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 41 | $1,084,715 |
| GattexTeduglutide | 12 | $605,781 |
| RinvoqUpadacitinib | 48 | $343,446 |
| LinzessLinaclotide | 195 | $163,275 |
| Humira(Cf) PenAdalimumab | 18 | $131,421 |
| RezdiffraResmetirom | 23 | $89,902 |
| RemicadeInfliximab | 15 | $85,373 |
| CreonLipase/Protease/Amylase | 33 | $73,286 |
| ZenpepLipase/Protease/Amylase | 13 | $25,110 |
| TrulancePlecanatide | 22 | $20,947 |
| OzempicSemaglutide | 19 | $18,150 |
| Dexlansoprazole DrDexlansoprazole | 46 | $14,477 |
| Sucralfate | 92 | $5,345 |
| Famotidine | 369 | $5,170 |
| Omeprazole | 342 | $4,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $1,299 | $1,170,08856 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $22,999 | $605,78112 claims |
| AbbVieRinvoq, Linzess, Creon | $36,094 | $580,007276 claims |
| Madrigal PharmaceuticalsRezdiffra | $853 | $89,90223 claims |
| Aimmune Therapeutics, Inc.Zenpep | $168 | $25,11013 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $1,713 | $20,94722 claims |
| Novo NordiskOzempic | $294 | $18,15019 claims |
| SandozLansoprazole | $83 | $26624 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $46 | $4615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 127 gastroenterology providers in Mississippi.
Other gastroenterology in Southaven
- Nabeel KhanSouthaven$552K
- Eric OrmsethSouthaven$9K
- Geza RemakSouthaven$8K
- Christopher GriffithSouthaven$6K
- Brian BorgJackson$1.7M
- Reed HoganFlowood$761K
- John RunnelsFlowood$591K
- Wassem JuakiemBiloxi$519K
- Stephen BuckleyHattiesburg$372K
- Reed HoganFlowood$369K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.